nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—NR3C1—Mometasone—systemic scleroderma	0.159	0.487	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Mometasone—systemic scleroderma	0.0548	0.168	CbGbCtD
Medroxyprogesterone Acetate—NR3C1—Prednisone—systemic scleroderma	0.0507	0.155	CbGbCtD
Medroxyprogesterone Acetate—Prednicarbate—Mometasone—systemic scleroderma	0.0474	0.101	CrCrCtD
Medroxyprogesterone Acetate—Fluoxymesterone—Mometasone—systemic scleroderma	0.0436	0.0932	CrCrCtD
Medroxyprogesterone Acetate—Fludrocortisone—Mometasone—systemic scleroderma	0.0424	0.0908	CrCrCtD
Medroxyprogesterone Acetate—Fluorometholone—Mometasone—systemic scleroderma	0.0394	0.0843	CrCrCtD
Medroxyprogesterone Acetate—Potassium Canrenoate—Prednisone—systemic scleroderma	0.0374	0.08	CrCrCtD
Medroxyprogesterone Acetate—Methylprednisolone—Mometasone—systemic scleroderma	0.0368	0.0788	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortisone—Mometasone—systemic scleroderma	0.0346	0.074	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortamate—Prednisone—systemic scleroderma	0.0275	0.0588	CrCrCtD
Medroxyprogesterone Acetate—Cortisone acetate—Prednisone—systemic scleroderma	0.0266	0.057	CrCrCtD
Medroxyprogesterone Acetate—Prednicarbate—Prednisone—systemic scleroderma	0.0258	0.0553	CrCrCtD
Medroxyprogesterone Acetate—CYP2C9—Leflunomide—systemic scleroderma	0.0246	0.0753	CbGbCtD
Medroxyprogesterone Acetate—Fludrocortisone—Prednisone—systemic scleroderma	0.0231	0.0495	CrCrCtD
Medroxyprogesterone Acetate—Methyltestosterone—Prednisone—systemic scleroderma	0.0225	0.0482	CrCrCtD
Medroxyprogesterone Acetate—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0218	0.0667	CbGbCtD
Medroxyprogesterone Acetate—Fluorometholone—Prednisone—systemic scleroderma	0.0215	0.046	CrCrCtD
Medroxyprogesterone Acetate—Methylprednisolone—Prednisone—systemic scleroderma	0.0201	0.0429	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortisone—Prednisone—systemic scleroderma	0.0189	0.0403	CrCrCtD
Medroxyprogesterone Acetate—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00885	0.027	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—cardial valve—systemic scleroderma	0.0078	0.274	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Prednisone—systemic scleroderma	0.00707	0.0216	CbGbCtD
Medroxyprogesterone Acetate—HSD3B2—digestive system—systemic scleroderma	0.00207	0.0726	CbGeAlD
Medroxyprogesterone Acetate—PGR—artery—systemic scleroderma	0.00205	0.0719	CbGeAlD
Medroxyprogesterone Acetate—PGR—blood vessel—systemic scleroderma	0.00159	0.056	CbGeAlD
Medroxyprogesterone Acetate—ESR1—blood vessel—systemic scleroderma	0.00125	0.0438	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—smooth muscle tissue—systemic scleroderma	0.0011	0.0388	CbGeAlD
Medroxyprogesterone Acetate—SHBG—connective tissue—systemic scleroderma	0.000907	0.0319	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—tendon—systemic scleroderma	0.000829	0.0291	CbGeAlD
Medroxyprogesterone Acetate—PGR—connective tissue—systemic scleroderma	0.000817	0.0287	CbGeAlD
Medroxyprogesterone Acetate—PGR—smooth muscle tissue—systemic scleroderma	0.000748	0.0263	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—lung—systemic scleroderma	0.000728	0.0256	CbGeAlD
Medroxyprogesterone Acetate—AR—connective tissue—systemic scleroderma	0.000651	0.0229	CbGeAlD
Medroxyprogesterone Acetate—ESR1—connective tissue—systemic scleroderma	0.000639	0.0225	CbGeAlD
Medroxyprogesterone Acetate—AR—smooth muscle tissue—systemic scleroderma	0.000596	0.0209	CbGeAlD
Medroxyprogesterone Acetate—AR—skin of body—systemic scleroderma	0.000588	0.0207	CbGeAlD
Medroxyprogesterone Acetate—ESR1—smooth muscle tissue—systemic scleroderma	0.000585	0.0205	CbGeAlD
Medroxyprogesterone Acetate—PGR—lung—systemic scleroderma	0.000493	0.0173	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—connective tissue—systemic scleroderma	0.000472	0.0166	CbGeAlD
Medroxyprogesterone Acetate—AR—digestive system—systemic scleroderma	0.00047	0.0165	CbGeAlD
Medroxyprogesterone Acetate—ESR1—digestive system—systemic scleroderma	0.000462	0.0162	CbGeAlD
Medroxyprogesterone Acetate—AR—tendon—systemic scleroderma	0.000447	0.0157	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—smooth muscle tissue—systemic scleroderma	0.000431	0.0152	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—skin of body—systemic scleroderma	0.000426	0.015	CbGeAlD
Medroxyprogesterone Acetate—AR—lung—systemic scleroderma	0.000393	0.0138	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lung—systemic scleroderma	0.000386	0.0135	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—digestive system—systemic scleroderma	0.000341	0.012	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—digestive system—systemic scleroderma	0.000338	0.0119	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—tendon—systemic scleroderma	0.000324	0.0114	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—lung—systemic scleroderma	0.000284	0.00999	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—digestive system—systemic scleroderma	0.000258	0.00905	CbGeAlD
Medroxyprogesterone Acetate—Weight decreased—Prednisone—systemic scleroderma	6.66e-05	0.000377	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	6.65e-05	0.000377	CcSEcCtD
Medroxyprogesterone Acetate—Hyperglycaemia—Prednisone—systemic scleroderma	6.64e-05	0.000376	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Lisinopril—systemic scleroderma	6.59e-05	0.000373	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Captopril—systemic scleroderma	6.58e-05	0.000373	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Mycophenolate mofetil—systemic scleroderma	6.56e-05	0.000371	CcSEcCtD
Medroxyprogesterone Acetate—Depression—Prednisone—systemic scleroderma	6.54e-05	0.000371	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Leflunomide—systemic scleroderma	6.52e-05	0.000369	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Leflunomide—systemic scleroderma	6.48e-05	0.000367	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Leflunomide—systemic scleroderma	6.48e-05	0.000367	CcSEcCtD
Medroxyprogesterone Acetate—Acute coronary syndrome—Prednisone—systemic scleroderma	6.47e-05	0.000366	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Mycophenolic acid—systemic scleroderma	6.45e-05	0.000365	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Mycophenolate mofetil—systemic scleroderma	6.44e-05	0.000365	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Mycophenolate mofetil—systemic scleroderma	6.44e-05	0.000365	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Mycophenolate mofetil—systemic scleroderma	6.44e-05	0.000365	CcSEcCtD
Medroxyprogesterone Acetate—Myocardial infarction—Prednisone—systemic scleroderma	6.43e-05	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Prednisone—systemic scleroderma	6.43e-05	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—Breast disorder—Methotrexate—systemic scleroderma	6.43e-05	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	6.42e-05	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Mycophenolate mofetil—systemic scleroderma	6.42e-05	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Azathioprine—systemic scleroderma	6.4e-05	0.000362	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	6.4e-05	0.000362	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	6.4e-05	0.000362	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Lisinopril—systemic scleroderma	6.38e-05	0.000361	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Mycophenolate mofetil—systemic scleroderma	6.37e-05	0.00036	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Lisinopril—systemic scleroderma	6.33e-05	0.000358	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Captopril—systemic scleroderma	6.33e-05	0.000358	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Mycophenolate mofetil—systemic scleroderma	6.3e-05	0.000357	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Lisinopril—systemic scleroderma	6.28e-05	0.000356	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Captopril—systemic scleroderma	6.28e-05	0.000355	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Captopril—systemic scleroderma	6.27e-05	0.000355	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Lisinopril—systemic scleroderma	6.27e-05	0.000355	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Captopril—systemic scleroderma	6.24e-05	0.000353	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Mycophenolate mofetil—systemic scleroderma	6.23e-05	0.000353	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Lisinopril—systemic scleroderma	6.2e-05	0.000351	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Mycophenolic acid—systemic scleroderma	6.19e-05	0.00035	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Mycophenolic acid—systemic scleroderma	6.19e-05	0.00035	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Mycophenolate mofetil—systemic scleroderma	6.18e-05	0.00035	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	6.18e-05	0.00035	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Methotrexate—systemic scleroderma	6.15e-05	0.000348	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Mycophenolate mofetil—systemic scleroderma	6.14e-05	0.000347	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Lisinopril—systemic scleroderma	6.13e-05	0.000347	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Lisinopril—systemic scleroderma	6.09e-05	0.000345	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Lisinopril—systemic scleroderma	6.08e-05	0.000344	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Mycophenolate mofetil—systemic scleroderma	6.08e-05	0.000344	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	6.06e-05	0.000343	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	6.05e-05	0.000342	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Leflunomide—systemic scleroderma	6.04e-05	0.000342	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Lisinopril—systemic scleroderma	6.03e-05	0.000341	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Mycophenolate mofetil—systemic scleroderma	6.03e-05	0.000341	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Mycophenolate mofetil—systemic scleroderma	6e-05	0.00034	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Prednisone—systemic scleroderma	6e-05	0.00034	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	5.97e-05	0.000338	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Azathioprine—systemic scleroderma	5.94e-05	0.000337	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Prednisone—systemic scleroderma	5.92e-05	0.000335	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Captopril—systemic scleroderma	5.91e-05	0.000335	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal discomfort—Methotrexate—systemic scleroderma	5.9e-05	0.000334	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Prednisone—systemic scleroderma	5.89e-05	0.000334	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Mycophenolate mofetil—systemic scleroderma	5.89e-05	0.000333	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Leflunomide—systemic scleroderma	5.89e-05	0.000333	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Lisinopril—systemic scleroderma	5.81e-05	0.000329	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Leflunomide—systemic scleroderma	5.8e-05	0.000329	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Prednisone—systemic scleroderma	5.79e-05	0.000328	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Mycophenolate mofetil—systemic scleroderma	5.77e-05	0.000327	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Lisinopril—systemic scleroderma	5.76e-05	0.000326	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Methotrexate—systemic scleroderma	5.75e-05	0.000326	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Azathioprine—systemic scleroderma	5.74e-05	0.000325	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Methotrexate—systemic scleroderma	5.72e-05	0.000324	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	5.63e-05	0.000319	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Mycophenolic acid—systemic scleroderma	5.61e-05	0.000318	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Leflunomide—systemic scleroderma	5.61e-05	0.000318	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Lisinopril—systemic scleroderma	5.6e-05	0.000317	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Mycophenolate mofetil—systemic scleroderma	5.59e-05	0.000316	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Lisinopril—systemic scleroderma	5.57e-05	0.000315	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Lisinopril—systemic scleroderma	5.57e-05	0.000315	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	5.55e-05	0.000314	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Mycophenolic acid—systemic scleroderma	5.54e-05	0.000313	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Azathioprine—systemic scleroderma	5.52e-05	0.000313	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Prednisone—systemic scleroderma	5.51e-05	0.000312	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	5.51e-05	0.000312	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Mycophenolate mofetil—systemic scleroderma	5.49e-05	0.000311	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Methotrexate—systemic scleroderma	5.49e-05	0.000311	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Methotrexate—systemic scleroderma	5.49e-05	0.000311	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Methotrexate—systemic scleroderma	5.49e-05	0.000311	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Azathioprine—systemic scleroderma	5.48e-05	0.00031	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Azathioprine—systemic scleroderma	5.47e-05	0.00031	CcSEcCtD
Medroxyprogesterone Acetate—Depression—Methotrexate—systemic scleroderma	5.47e-05	0.00031	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Azathioprine—systemic scleroderma	5.44e-05	0.000308	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	5.44e-05	0.000308	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Leflunomide—systemic scleroderma	5.42e-05	0.000307	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	5.37e-05	0.000304	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Mycophenolic acid—systemic scleroderma	5.35e-05	0.000303	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Methotrexate—systemic scleroderma	5.35e-05	0.000303	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Prednisone—systemic scleroderma	5.35e-05	0.000303	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	5.33e-05	0.000302	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Prednisone—systemic scleroderma	5.32e-05	0.000301	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Mycophenolate mofetil—systemic scleroderma	5.28e-05	0.000299	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Methotrexate—systemic scleroderma	5.26e-05	0.000298	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Leflunomide—systemic scleroderma	5.22e-05	0.000295	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Prednisone—systemic scleroderma	5.21e-05	0.000295	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Lisinopril—systemic scleroderma	5.19e-05	0.000294	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Methotrexate—systemic scleroderma	5.19e-05	0.000294	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Mycophenolic acid—systemic scleroderma	5.17e-05	0.000293	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Methotrexate—systemic scleroderma	5.17e-05	0.000293	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Leflunomide—systemic scleroderma	5.17e-05	0.000293	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Leflunomide—systemic scleroderma	5.17e-05	0.000293	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Prednisone—systemic scleroderma	5.16e-05	0.000292	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Azathioprine—systemic scleroderma	5.16e-05	0.000292	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Leflunomide—systemic scleroderma	5.14e-05	0.000291	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Prednisone—systemic scleroderma	5.13e-05	0.00029	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Prednisone—systemic scleroderma	5.13e-05	0.00029	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	5.09e-05	0.000288	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Lisinopril—systemic scleroderma	5.06e-05	0.000286	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	5.05e-05	0.000286	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Lisinopril—systemic scleroderma	4.99e-05	0.000282	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Mycophenolic acid—systemic scleroderma	4.98e-05	0.000282	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Methotrexate—systemic scleroderma	4.95e-05	0.00028	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Mycophenolic acid—systemic scleroderma	4.93e-05	0.000279	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Mycophenolic acid—systemic scleroderma	4.93e-05	0.000279	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Methotrexate—systemic scleroderma	4.92e-05	0.000279	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Methotrexate—systemic scleroderma	4.92e-05	0.000279	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Mycophenolate mofetil—systemic scleroderma	4.91e-05	0.000278	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Mycophenolic acid—systemic scleroderma	4.9e-05	0.000278	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Methotrexate—systemic scleroderma	4.89e-05	0.000277	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	4.88e-05	0.000276	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	4.88e-05	0.000276	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Leflunomide—systemic scleroderma	4.87e-05	0.000276	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Methotrexate—systemic scleroderma	4.86e-05	0.000275	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Methotrexate—systemic scleroderma	4.83e-05	0.000273	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Lisinopril—systemic scleroderma	4.82e-05	0.000273	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Prednisone—systemic scleroderma	4.76e-05	0.000269	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Methotrexate—systemic scleroderma	4.75e-05	0.000269	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Prednisone—systemic scleroderma	4.74e-05	0.000268	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Prednisone—systemic scleroderma	4.71e-05	0.000267	CcSEcCtD
Medroxyprogesterone Acetate—Angioedema—Prednisone—systemic scleroderma	4.69e-05	0.000265	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Lisinopril—systemic scleroderma	4.66e-05	0.000264	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Methotrexate—systemic scleroderma	4.66e-05	0.000264	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Mycophenolic acid—systemic scleroderma	4.65e-05	0.000263	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Prednisone—systemic scleroderma	4.63e-05	0.000262	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Prednisone—systemic scleroderma	4.61e-05	0.000261	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Methotrexate—systemic scleroderma	4.6e-05	0.000261	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Prednisone—systemic scleroderma	4.6e-05	0.00026	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Methotrexate—systemic scleroderma	4.59e-05	0.00026	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Methotrexate—systemic scleroderma	4.57e-05	0.000259	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	4.55e-05	0.000258	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Prednisone—systemic scleroderma	4.51e-05	0.000255	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Lisinopril—systemic scleroderma	4.48e-05	0.000254	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Methotrexate—systemic scleroderma	4.47e-05	0.000253	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Methotrexate—systemic scleroderma	4.45e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—FOXM1 transcription factor network—CENPB—systemic scleroderma	4.45e-05	0.128	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Lisinopril—systemic scleroderma	4.44e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Prednisone—systemic scleroderma	4.44e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Lisinopril—systemic scleroderma	4.44e-05	0.000251	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Methotrexate—systemic scleroderma	4.44e-05	0.000251	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Mycophenolate mofetil—systemic scleroderma	4.43e-05	0.000251	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Methotrexate—systemic scleroderma	4.42e-05	0.00025	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Lisinopril—systemic scleroderma	4.42e-05	0.00025	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Mycophenolate mofetil—systemic scleroderma	4.37e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Prednisone—systemic scleroderma	4.37e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Prednisone—systemic scleroderma	4.37e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Prednisone—systemic scleroderma	4.35e-05	0.000246	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Methotrexate—systemic scleroderma	4.35e-05	0.000246	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	4.34e-05	0.000246	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Prednisone—systemic scleroderma	4.31e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Methotrexate—systemic scleroderma	4.31e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Methotrexate—systemic scleroderma	4.29e-05	0.000243	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Methotrexate—systemic scleroderma	4.29e-05	0.000243	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	4.23e-05	0.000239	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Methotrexate—systemic scleroderma	4.2e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Lisinopril—systemic scleroderma	4.19e-05	0.000237	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Prednisone—systemic scleroderma	4.19e-05	0.000237	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Prednisone—systemic scleroderma	4.19e-05	0.000237	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Prednisone—systemic scleroderma	4.16e-05	0.000235	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Methotrexate—systemic scleroderma	4.15e-05	0.000235	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Prednisone—systemic scleroderma	4.12e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Prednisone—systemic scleroderma	4.11e-05	0.000232	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Prednisone—systemic scleroderma	4.09e-05	0.000231	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Mycophenolate mofetil—systemic scleroderma	4.08e-05	0.000231	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Prednisone—systemic scleroderma	4.07e-05	0.00023	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Prednisone—systemic scleroderma	4.05e-05	0.000229	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Prednisone—systemic scleroderma	3.99e-05	0.000226	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Methotrexate—systemic scleroderma	3.98e-05	0.000225	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Methotrexate—systemic scleroderma	3.96e-05	0.000224	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Mycophenolate mofetil—systemic scleroderma	3.93e-05	0.000222	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Mycophenolate mofetil—systemic scleroderma	3.89e-05	0.00022	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Mycophenolate mofetil—systemic scleroderma	3.89e-05	0.00022	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Mycophenolate mofetil—systemic scleroderma	3.87e-05	0.000219	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Methotrexate—systemic scleroderma	3.87e-05	0.000219	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Methotrexate—systemic scleroderma	3.85e-05	0.000218	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Prednisone—systemic scleroderma	3.81e-05	0.000216	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Prednisone—systemic scleroderma	3.79e-05	0.000214	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Prednisone—systemic scleroderma	3.76e-05	0.000213	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Methotrexate—systemic scleroderma	3.71e-05	0.00021	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Prednisone—systemic scleroderma	3.68e-05	0.000209	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Mycophenolate mofetil—systemic scleroderma	3.67e-05	0.000208	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Methotrexate—systemic scleroderma	3.65e-05	0.000207	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Methotrexate—systemic scleroderma	3.65e-05	0.000207	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Methotrexate—systemic scleroderma	3.65e-05	0.000207	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Prednisone—systemic scleroderma	3.64e-05	0.000206	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	3.62e-05	0.000205	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Prednisone—systemic scleroderma	3.61e-05	0.000204	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Methotrexate—systemic scleroderma	3.61e-05	0.000204	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Prednisone—systemic scleroderma	3.58e-05	0.000203	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Methotrexate—systemic scleroderma	3.53e-05	0.0002	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Methotrexate—systemic scleroderma	3.5e-05	0.000198	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Methotrexate—systemic scleroderma	3.48e-05	0.000197	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Prednisone—systemic scleroderma	3.45e-05	0.000195	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Methotrexate—systemic scleroderma	3.43e-05	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Methotrexate—systemic scleroderma	3.43e-05	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Prednisone—systemic scleroderma	3.42e-05	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Methotrexate—systemic scleroderma	3.4e-05	0.000192	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Methotrexate—systemic scleroderma	3.38e-05	0.000192	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Methotrexate—systemic scleroderma	3.33e-05	0.000189	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Prednisone—systemic scleroderma	3.33e-05	0.000188	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Prednisone—systemic scleroderma	3.31e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Prednisone—systemic scleroderma	3.31e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Methotrexate—systemic scleroderma	3.27e-05	0.000185	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	3.19e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Methotrexate—systemic scleroderma	3.16e-05	0.000179	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Methotrexate—systemic scleroderma	3.14e-05	0.000178	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Methotrexate—systemic scleroderma	3.12e-05	0.000177	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Methotrexate—systemic scleroderma	3.11e-05	0.000176	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Prednisone—systemic scleroderma	3.08e-05	0.000175	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Methotrexate—systemic scleroderma	3.08e-05	0.000174	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Methotrexate—systemic scleroderma	3.04e-05	0.000172	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Methotrexate—systemic scleroderma	3.02e-05	0.000171	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Methotrexate—systemic scleroderma	3.02e-05	0.000171	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Prednisone—systemic scleroderma	3e-05	0.00017	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Prednisone—systemic scleroderma	2.96e-05	0.000168	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Methotrexate—systemic scleroderma	2.88e-05	0.000163	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Prednisone—systemic scleroderma	2.86e-05	0.000162	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Methotrexate—systemic scleroderma	2.86e-05	0.000162	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Methotrexate—systemic scleroderma	2.78e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Prednisone—systemic scleroderma	2.77e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Methotrexate—systemic scleroderma	2.77e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Methotrexate—systemic scleroderma	2.77e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Prednisone—systemic scleroderma	2.66e-05	0.000151	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Prednisone—systemic scleroderma	2.64e-05	0.000149	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Prednisone—systemic scleroderma	2.64e-05	0.000149	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Prednisone—systemic scleroderma	2.62e-05	0.000148	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Methotrexate—systemic scleroderma	2.58e-05	0.000146	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Methotrexate—systemic scleroderma	2.51e-05	0.000142	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Prednisone—systemic scleroderma	2.49e-05	0.000141	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Methotrexate—systemic scleroderma	2.48e-05	0.00014	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Methotrexate—systemic scleroderma	2.39e-05	0.000136	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Methotrexate—systemic scleroderma	2.31e-05	0.000131	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Methotrexate—systemic scleroderma	2.22e-05	0.000126	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Methotrexate—systemic scleroderma	2.21e-05	0.000125	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Methotrexate—systemic scleroderma	2.2e-05	0.000125	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Methotrexate—systemic scleroderma	2.19e-05	0.000124	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Retinoid metabolism and transport—HSPG2—systemic scleroderma	2.16e-05	0.062	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Methotrexate—systemic scleroderma	2.08e-05	0.000118	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—FOXM1 transcription factor network—CENPA—systemic scleroderma	1.17e-05	0.0338	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Diseases associated with visual transduction—HSPG2—systemic scleroderma	1.1e-05	0.0317	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—SMAD7—systemic scleroderma	1.03e-05	0.0296	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—SMAD7—systemic scleroderma	7.93e-06	0.0228	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Cellular roles of Anthrax toxin—IL1B—systemic scleroderma	7.85e-06	0.0226	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—SMAD7—systemic scleroderma	7.81e-06	0.0225	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Corticotropin-releasing hormone—NOS3—systemic scleroderma	7.54e-06	0.0217	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—COL1A2—systemic scleroderma	7.51e-06	0.0216	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—RHOB—systemic scleroderma	7.39e-06	0.0213	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—COL1A2—systemic scleroderma	6.51e-06	0.0187	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—COL1A2—systemic scleroderma	6.41e-06	0.0184	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	6.26e-06	0.018	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	5.82e-06	0.0167	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—COL1A2—systemic scleroderma	5.79e-06	0.0167	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—COL1A2—systemic scleroderma	5.7e-06	0.0164	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.32e-06	0.0153	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	4.99e-06	0.0144	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—IL13—systemic scleroderma	4.83e-06	0.0139	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	4.82e-06	0.0139	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	4.48e-06	0.0129	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.03e-06	0.0116	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—IL13—systemic scleroderma	3.81e-06	0.0109	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—EDN1—systemic scleroderma	3.52e-06	0.0101	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—MMP2—systemic scleroderma	3.51e-06	0.0101	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—EDN1—systemic scleroderma	3.47e-06	0.00998	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—FOXM1 transcription factor network—MMP2—systemic scleroderma	3.45e-06	0.00992	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—SMAD7—systemic scleroderma	3.38e-06	0.00973	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—NOS3—systemic scleroderma	3.29e-06	0.00947	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—MMP1—systemic scleroderma	2.96e-06	0.00852	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—MMP1—systemic scleroderma	2.92e-06	0.00839	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—IL13—systemic scleroderma	2.89e-06	0.00831	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—systemic scleroderma	2.67e-06	0.00769	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—MMP9—systemic scleroderma	2.64e-06	0.0076	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.63e-06	0.00756	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—ATF-2 transcription factor network—MMP2—systemic scleroderma	2.63e-06	0.00756	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—SMAD7—systemic scleroderma	2.58e-06	0.00741	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	2.57e-06	0.00739	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—CCL2—systemic scleroderma	2.41e-06	0.00693	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	2.39e-06	0.00689	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—CCL2—systemic scleroderma	2.37e-06	0.00682	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—HSPG2—systemic scleroderma	2.37e-06	0.00682	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	2.08e-06	0.00598	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—NOS3—systemic scleroderma	2.03e-06	0.00584	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—systemic scleroderma	2.01e-06	0.00578	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.99e-06	0.00573	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—SMAD7—systemic scleroderma	1.98e-06	0.00571	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—SMAD7—systemic scleroderma	1.95e-06	0.00562	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—SMAD7—systemic scleroderma	1.92e-06	0.00551	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—CTGF—systemic scleroderma	1.87e-06	0.00538	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	1.82e-06	0.00523	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—CTGF—systemic scleroderma	1.8e-06	0.00517	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—TGFBI—systemic scleroderma	1.75e-06	0.00504	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—IL1B—systemic scleroderma	1.73e-06	0.00497	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—MMP9—systemic scleroderma	1.72e-06	0.00495	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—MMP9—systemic scleroderma	1.7e-06	0.00488	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—SMAD7—systemic scleroderma	1.63e-06	0.00468	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	1.6e-06	0.00461	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—TNFSF13—systemic scleroderma	1.51e-06	0.00435	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—TGFB1—systemic scleroderma	1.45e-06	0.00418	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Endoderm Differentiation—TGFB1—systemic scleroderma	1.43e-06	0.00412	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—CTGF—systemic scleroderma	1.42e-06	0.0041	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—TGFB1—systemic scleroderma	1.42e-06	0.00408	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—HSPG2—systemic scleroderma	1.4e-06	0.00402	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—TGFB1—systemic scleroderma	1.4e-06	0.00402	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CSK—systemic scleroderma	1.35e-06	0.00388	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SMAD7—systemic scleroderma	1.34e-06	0.00386	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CD247—systemic scleroderma	1.27e-06	0.00365	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	1.25e-06	0.00359	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—SMAD7—systemic scleroderma	1.24e-06	0.00357	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—HSPG2—systemic scleroderma	1.17e-06	0.00337	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—TNFSF13—systemic scleroderma	1.15e-06	0.00332	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—CTGF—systemic scleroderma	1.1e-06	0.00316	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—CTGF—systemic scleroderma	1.08e-06	0.00311	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SMAD7—systemic scleroderma	1.06e-06	0.00305	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—RHOB—systemic scleroderma	1.04e-06	0.00299	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—HSPG2—systemic scleroderma	9.79e-07	0.00282	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—SMAD7—systemic scleroderma	9.55e-07	0.00275	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	9.47e-07	0.00273	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CSK—systemic scleroderma	9.45e-07	0.00272	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—SMAD7—systemic scleroderma	9.41e-07	0.00271	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—CTGF—systemic scleroderma	9e-07	0.00259	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—TNFSF13—systemic scleroderma	8.88e-07	0.00256	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—CTGF—systemic scleroderma	8.87e-07	0.00255	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—TNFSF13—systemic scleroderma	8.75e-07	0.00252	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—TGFB1—systemic scleroderma	8.52e-07	0.00245	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	8.25e-07	0.00237	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—RHOB—systemic scleroderma	8.19e-07	0.00236	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—NOS3—systemic scleroderma	7.82e-07	0.00225	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—HSPG2—systemic scleroderma	7.72e-07	0.00222	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CSK—systemic scleroderma	7.46e-07	0.00215	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	7.39e-07	0.00213	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—CTGF—systemic scleroderma	6.86e-07	0.00197	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	6.36e-07	0.00183	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SMAD7—systemic scleroderma	6.21e-07	0.00179	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.01e-07	0.00173	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.6e-07	0.00161	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—EDN1—systemic scleroderma	5.3e-07	0.00152	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—CTGF—systemic scleroderma	5.28e-07	0.00152	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—CTGF—systemic scleroderma	5.2e-07	0.0015	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RHOB—systemic scleroderma	4.81e-07	0.00138	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—NOS3—systemic scleroderma	4.61e-07	0.00133	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.56e-07	0.00131	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HSPG2—systemic scleroderma	4.53e-07	0.0013	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CSK—systemic scleroderma	4.38e-07	0.00126	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—EDN1—systemic scleroderma	4.18e-07	0.0012	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—NOS3—systemic scleroderma	3.86e-07	0.00111	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CCL2—systemic scleroderma	3.62e-07	0.00104	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—HSPG2—systemic scleroderma	3.29e-07	0.000947	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NOS3—systemic scleroderma	3.23e-07	0.000929	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—TGFB1—systemic scleroderma	3.05e-07	0.000877	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CCL2—systemic scleroderma	2.86e-07	0.000822	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HSPG2—systemic scleroderma	2.68e-07	0.000771	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MMP9—systemic scleroderma	2.59e-07	0.000745	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NOS3—systemic scleroderma	2.55e-07	0.000733	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CTGF—systemic scleroderma	2.49e-07	0.000718	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EDN1—systemic scleroderma	2.45e-07	0.000706	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TGFB1—systemic scleroderma	2.14e-07	0.000614	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MMP9—systemic scleroderma	2.04e-07	0.000588	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CTGF—systemic scleroderma	2.03e-07	0.000584	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.77e-07	0.000508	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TGFB1—systemic scleroderma	1.68e-07	0.000485	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CCL2—systemic scleroderma	1.68e-07	0.000483	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NOS3—systemic scleroderma	1.49e-07	0.00043	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.34e-07	0.000385	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MMP9—systemic scleroderma	1.2e-07	0.000345	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NOS3—systemic scleroderma	1.09e-07	0.000312	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TGFB1—systemic scleroderma	9.88e-08	0.000284	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NOS3—systemic scleroderma	8.84e-08	0.000254	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NOS3—systemic scleroderma	5.83e-08	0.000168	CbGpPWpGaD
